Erratum: In vivo PET Imaging demonstrates diminished microglial activation after fingolimod treatment in an animal model of multiple sclerosis (Journal of Nuclear Medicine (2015) 56 (305–310) DOI: 10.2967/jnumed.114.149955);In vivo PET imaging demonstrates diminished microglial activation after fingolimod treatment in an animal model of multiple sclerosis

Journal of Nuclear Medicine

Volumn 56, Issue 2, 2015, Pages 305-310

  Airas, Laura ^a,d   Dickens, Alex M ^b   Elo, Petri ^b   Marjamäki, Päivi ^b   Johansson, Jarkko ^b   Eskola, Olli ^b   Jones, Paul A ^c   Trigg, William ^c   Solin, Olof ^b   Haaparanta Solin, Merja ^b   Anthony, Daniel C ^d   Rinne, Juha ^b  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c GE HEALTHCARE   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Fingolimod; Multiple sclerosis; Neuroinflammation; PET imaging; TSPO

Indexed keywords

BCG VACCINE; FINGOLIMOD; FREUND ADJUVANT; GE 180 F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 4 AMINOBUTYRIC ACID A RECEPTOR; BZRP PROTEIN, RAT; CARRIER PROTEIN; IMMUNOSUPPRESSIVE AGENT; LIGAND; PROPANEDIOL DERIVATIVE; SPHINGOSINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; CELL ACTIVATION; CHRONIC DISEASE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; EX VIVO STUDY; EXPERIMENTAL AUTOIMMUNE ENCEPHALITITS; EXPERIMENTAL NEUROLOGIC DISEASE; HEMISPHERE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LIGAND BINDING; MALE; MICROGLIA; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PROTEIN BINDING; RADIOASSAY; RAT; STEREOTACTIC PROCEDURE; TREATMENT DURATION; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; DISEASE MODEL; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; INFLAMMATION; LEWIS RAT; SCINTISCANNING; TIME;

ANIMALS; AUTORADIOGRAPHY; BCG VACCINE; CARRIER PROTEINS; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FREUND'S ADJUVANT; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; LIGANDS; MALE; MICROGLIA; MULTIPLE SCLEROSIS; POSITRON-EMISSION TOMOGRAPHY; PROPYLENE GLYCOLS; RATS; RATS, INBRED LEW; RECEPTORS, GABA-A; SPHINGOSINE; TIME FACTORS;

EID: 84922032983     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.149955     Document Type: Erratum

References (35)

1. Sormani MP, Bruzzi P. MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials. Lancet Neurol. 2013;12:669-676.
2. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med. 2000;343:1430-1438.
3. Howell OW, Rundle JL, Garg A, Komada M, Brophy PJ. Reynolds R. Activated microglia mediate axoglial disruption that contributes to axonal injury in multiple sclerosis. J Neuropathol Exp Neurol. 2010;69:1017-1033.
4. Barkhof F. The clinico-radiological paradox in multiple sclerosis revisited. Curr Opin Neurol. 2002;15:239-245.
5. Papadopoulos V, Baraldi M, Guilarte TR, et al. Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci. 2006;27:402-409.
6. Chen MK, Baidoo K, Verina T, Guilarte TR. Peripheral benzodiazepine receptor imaging in CNS demyelination: functional implications of anatomical and cellular localization. Brain. 2004;127:1379-1392.
7. Politis M, Giannetti P, Su P, et al. Increased PK11195 PET binding in the cortex of patients with MS correlates with disability. Neurology. 2012;79:523-530.
8. Banati RB. Visualising microglial activation in vivo. Glia. 2002;40:206-217.
9. Rissanen E, Tuisku J, Rokka J, et al. In vivo detection of diffuse inflammation in secondary progressive multiple sclerosis using PET imaging and the radioligand 11C-PK11195. J Nucl Med. 2014;55:939-944.
10. Ching AS, Kuhnast B, Damont A, Roeda D, Tavitian B, Dolle F. Current paradigm of the 18-kDa translocator protein (TSPO) as a molecular target for PET imaging in neuroinflammation and neurodegenerative diseases. Insights Imaging. 2012;3:111-119.
11. 18F-GE-180. J Nucl Med. 2014;55:466-472.
12. 18F]GE-180; a radiotracer for imaging translocator protein (TSPO). J Labelled Comp Radiopharm. 2014;57:42-48.
13. Jeffery DR. Recent advances in treating multiple sclerosis: efficacy, risks and place in therapy. Ther Adv Chronic Dis. 2013;4:45-51.
14. Brinkmann V, Davis MD, Heise CE, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem. 2002;277:21453-21457.
15. Cohen JA, Chun J. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann Neurol. 2011;69:759-777.
16. Foster CA, Howard LM, Schweitzer A, et al. Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J Pharmacol Exp Ther. 2007;323:469-475.
17. Coelho RP, Payne SG, Bittman R, Spiegel S, Sato-Bigbee C. The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors. J Pharmacol Exp Ther. 2007;323:626-635.
18. Serres S, Anthony DC, Jiang Y, et al. Comparison of MRI signatures in pattern I and II multiple sclerosis models. NMR Biomed. 2009;22:1014-1024.
19. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000;47:707-717.
20. Anthony DC, Miller KM, Fearn S, et al. Matrix metalloproteinase expression in an experimentally-induced DTH model of multiple sclerosis in the rat CNS. J Neuroimmunol. 1998;87:62-72.
21. Caporale V, Alessandrini B, Villa P, Del Papa S. Global perspectives on animal welfare: Europe. Rev Sci Tech. 2005;24:567-577.
22. Matyszak MK, Perry VH. Demyelination in the central nervous system following a delayed-type hypersensitivity response to bacillus Calmette-Guérin. Neuroscience. 1995;64:967-977.
23. Anthony DC, Sibson NR, Losey P, Meier DP, Leppert D. Investigation of immune and CNS-mediated effects of fingolimod in the focal delayed-type hypersensitivity multiple sclerosis model. Neuropharmacology. 2014;79:534-541.
24. McLean IW, Nakane PK. Periodate-lysine-paraformaldehyde fixative: a new fixation for immunoelectron microscopy. J Histochem Cytochem. 1974;22:1077-1083.
25. Farde L, Eriksson L, Blomqvist G, Halldin C. Kinetic analysis of central 11Craclopride binding to D2-dopamine receptors studied by PET: a comparison to the equilibrium analysis. J Cereb Blood Flow Metab. 1989;9:696-708.
26. Cosenza-Nashat M, Zhao ML, Suh HS, et al. Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain. Neuropathol Appl Neurobiol. 2009;35:306-328.
27. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362:402-415.
28. Mehling M, Kappos L, Derfuss T. Fingolimod for multiple sclerosis: mechanism of action, clinical outcomes, and future directions. Curr Neurol Neurosci Rep. 2011;11:492-497.
29. Groves A, Kihara Y, Chun J. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy. J Neurol Sci. 2013;328:9-18.
30. Frischer JM, Bramow S, Dal-Bianco A, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain. 2009;132:1175-1189.
31. Prineas JW, Kwon EE, Cho ES, et al. Immunopathology of secondary-progressive multiple sclerosis. Ann Neurol. 2001;50:646-657.
32. Magliozzi R, Howell OW, Reeves C, et al. A gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol. 2010;68:477-493.
33. Ratchford JN, Endres CJ, Hammoud DA, et al. Decreased microglial activation in MS patients treated with glatiramer acetate. J Neurol. 2012;259:1199-1205.
34. Serres S, Anthony DC, Jiang Y, et al. Systemic inflammatory response reactivates immune-mediated lesions in rat brain. J Neurosci. 2009;29:4820-4828.
35. Levin CS, Hoffman EJ. Calculation of positron range and its effect on the fundamental limit of positron emission tomography system spatial resolution. Phys Med Biol. 1999;44:781-799.